中文名 | VX-765 |
英文名 | VX-765 |
别名 | N-(4-氨基-3-氯苯甲酰基)-3-甲基-L-缬氨酰-N-[(2R,3S)-2-乙氧基四氢-5-氧代-3-呋喃基]-L-脯氨酰胺 N-(4-氨基-3-氯苯甲酰基)-3-甲基-L-缬氨酰-N-[(2R,3S)-2-乙氧基四氢-5-氧代-3-呋喃基]-L-脯氨酰胺 5级 N-(4-氨基-3-氯苯甲酰基)-3-甲基-L-缬氨酰-N-[(2R,3S)-2-乙氧基四氢-5-氧代-3-呋喃基]-L-脯氨酰胺 3级 |
英文别名 | CS-387 VX-765 VX 765 VX-765 N-(4-Amino-3-chlorobenzoyl)-3-methyl-L-valyl-N-[(2R,3S)-2-ethoxytetrahydro-5-oxo-3-furanyl]-L-prolinamide L-Prolinamide, N-(4-amino-3-chlorobenzoyl)-3-methyl-L-valyl-N-[(2R,3S)-2-ethoxytetrahydro-5-oxo-3-furanyl]- (S)-1-((S)-2-(4-amino-3-chlorobenzamido)-3,3-dimethylbutanoyl)-N-((2R,3S)-2-ethoxy-5-oxotetrahydrofuran-3-yl)pyrrolidine-2-carboxamide (2S)-1-[(2S)-2-[(4-amino-3-chlorophenyl)formamido]-3,3-dimethylbutanoyl]-N-[(2R,3S)-2-ethoxy-5-oxooxolan-3-yl]pyrrolidine-2-carboxamide |
CAS | 273404-37-8 |
化学式 | C24H33ClN4O6 |
分子量 | 508.99 |
密度 | 1.32 |
沸点 | 779.0±60.0 °C(Predicted) |
溶解度 | 溶于DMSO (>25 mg/ml) |
酸度系数 | 12.60±0.40(Predicted) |
存储条件 | -20°C |
稳定性 | 稳定1年的供应。DMSO中的溶液可以在-20 °C下储存长达3个月。 |
外观 | 固体 |
颜色 | Off-white to white |
体外研究 | VX-765 is an orally absorbed prodrug of VRT-043198, which exhibits potent inhibition against ICE/caspase-1 and caspase-4 with Ki of 0.8 nM and less than 0.6 nM, respectively. And VRT-043198 also inhibits IL-1β release from both PBMCs and whole blood with IC50 of 0.67 μM and 1.9 μM, respectively. VX-765是一种口服可吸收的VRT-043198前药,其对ICE/caspase-1 和caspase-4表现出有效的抑制作用,Ki 分别为0.8 nM 和<0.6 nM。VRT-043198也会抑制IL-1β从PBMCs和全血中的释放,IC50分别为0.67 μM 和1.9 μM。 |
体内研究 | In collagen-induced arthritis mouse model, VX-765 (200 mg/kg) inhibits LPS-induced IL-1β production by about 60%, and results in a dose-dependent, statistically significant reduction in the inflammation scores and effective protection from joint changes. In vivo, VX-765 blocks kindling epileptogenesis in rats by preventing IL-1β increase in forebrain astrocytes without significant effect on afterdischarge duration. In the mouse model of acute seizures, VX-765 (50 mg/kg-200 mg/kg) produces the anticonvulsant effect by delaying the time to onset of the first seizure and decreasing the number of seizures as well as their total duration by average 50% and 64%. In adult rats with genetic absence epilepsy (GAERS), VX-765, after the 3rd drug injection, significantly reduces the cumulative duration and number of spike-and-wave discharges (SWDs) by 55% on average by selectively blocking IL-1β biosynthesis. 在胶原诱导的关节炎小鼠模型中,VX-765 (200 mg/kg)抑制60% LPS诱导的IL-1β产生,并导致炎症比例剂量依赖性显著减少,对关节病变也能够产生有效保护作用。在体内,VX-765通过防止前脑星形胶质细胞中IL-1β的增加阻断大鼠体内的癫痫发生,而对后放电持续时间没有显著影响。在急性癫痫小鼠模型中,VX-765 (50 mg/kg-200 mg/kg)通过延迟首次癫痫开始时间,并减少平均50%的癫痫发作次数以及64%的总持续时间,产生抗痉挛作用。在患有遗传性失神癫痫的成年大鼠体内,VX-765药物注射3天后,通过选择性阻断IL-1β生物合成,显著降低累积持续时间和平均55%的棘慢波放电(SWDs)。 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 1.965 ml | 9.823 ml | 19.646 ml |
5 mM | 0.393 ml | 1.965 ml | 3.929 ml |
10 mM | 0.196 ml | 0.982 ml | 1.965 ml |
5 mM | 0.039 ml | 0.196 ml | 0.393 ml |
微信搜索化工百科或扫描下方二维码,添加化工百科小程序,随时随地查信息!